Amendments to the Claims and Listing of the Claims:

This listing of the claims will replace all prior versions and listings of claims in this application.

- 1. (Currently Amended) A method of treating a patient suffering from severe glaucoma, exhibiting optical nerve head damage and visual field defects, comprising simultaneously administering a combination of IOP reducing agents <u>latanoprost and timolol</u> to the patient's eye, wherein at least one IOP reducing agent comprises a prostaglandin or a prostaglandin derivative and at least one IOP reducing agent comprises a beta-adrenergic antagonist or carbonic anhydrase inhibitor.
- 2. (Original) A method according to claim 1, wherein said combination is administered to the surface of the eye.
- 3. (Currently Amended) A method according to claim 2, wherein said combination is a topical ophthalmic composition comprising a mixture of IOP-reducing agents.
 - 4. (Canceled).
- 5. (Previously Presented) A method according to claim 1, wherein improved efficacy in IOP reduction is obtained in the patient when compared to patients suffering from an elevated IOP, but being free from abnormalities in the optical nerve head and visual field loss.
- 6. (Currently Amended) A method according to claim 1, wherein said combination comprises 50 µg/mL latanoprost and 5 mg/mL timolol an effective amount of an IOP-reducing agent capable of increasing the uveoscleral outflow of aqueous humor.
 - 7-80. (Canceled).